HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive form of cancer that arises in the cells lining the ducts of the pancreas. It accounts for the majority of pancreatic cancer cases and is known for its late-stage diagnosis and poor prognosis. Typically asymptomatic in its early stages, PDAC often goes unnoticed until it reaches an advanced state, making it challenging to treat effectively. Common symptoms may include abdominal pain, weight loss, jaundice, and digestive issues. Risk factors for PDAC include age, smoking, family history of pancreatic cancer, and certain genetic mutations. Despite ongoing research, the exact cause of PDAC remains elusive. Diagnosis often involves imaging tests, biopsies, and blood markers. Unfortunately, by the time PDAC is diagnosed, it has usually spread beyond the pancreas, limiting treatment options. Surgical intervention, chemotherapy, and radiation therapy are commonly employed to manage the disease, but the overall survival rate remains low. Due to its aggressive nature and lack of early symptoms, raising awareness about risk factors, early detection methods, and the importance of regular check-ups is crucial in improving outcomes for individuals at risk of developing pancreatic ductal adenocarcinoma. Ongoing research efforts aim to uncover new treatment modalities and enhance our understanding of the disease to improve patient outcomes in the future.
